Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
11.46 ^CNY	+9.98%		+18.14%	-24.70%

Apr. 25	Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Qingdao Vland Biotech INC. announced that it has received CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd.

April 06, 2021

On April 7, 2021, Qingdao Vland Biotech INC. (SHSE:603739) closed the transaction. The company paid issuance cost of CNY 4,045,283.04 and received net proceeds of CNY 495,954,700.96 in the transaction.

Latest news about Qingdao Vland Biotech INC.

Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik	23-10-13	MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.	23-08-15	CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan	23-07-21	MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.	23-07-20	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant	23-03-24	MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.	21-10-18	CI
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group	21-10-18	MT
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-16	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-20	CI
Qingdao Vland Biotech INC. announced that it has received CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd.	21-04-06	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
Qingdao Vland Biotech INC. announced that it expects to receive CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd.	20-10-15	CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-26	CI
Qingdao Vland Biological Products Co., Ltd. announced that it has received CNY 430 million in funding from Qingdao Vland Biotech INC.	20-05-25	CI

Chart Qingdao Vland Biotech INC.

Duration

Period

More charts

Company Profile

Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Qingdao Vland Biotech INC.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.46

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
QINGDAO VLAND BIOTECH INC.	-24.70%	400M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs